

**Title:** Potential for person-to-person transmission of henipaviruses: A systematic review of the literature

**Authors:** Sonia Hegde<sup>1</sup>, Kyu Han Lee<sup>1</sup>, Ashley Styczynski<sup>2</sup>, Forrest K Jones<sup>1</sup>, Isabella Gomes<sup>1</sup>, Pritimoy Das<sup>3</sup>, Emily S. Gurley<sup>1\*</sup>

<sup>1</sup>Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA

<sup>2</sup>Division of Infectious Diseases & Geographic Medicine, Stanford University, Stanford, CA, USA

<sup>3</sup>Institute of Health and Wellbeing, Federation University Australia, Ballarat, Victoria, Australia

**Competing interests:** the authors declare no competing interests.

## Abstract

Nipah virus – Bangladesh (NiV<sub>B</sub>) is a bat-borne zoonosis transmitted between people through the respiratory route, posing a pandemic risk. The risk posed by related henipaviruses, including Hendra virus (HeV) and Nipah virus – Malaysia (NiV<sub>M</sub>) is less clear. We conducted a broad search of the literature encompassing both human infections and animal models to synthesize evidence about potential for person-to-person spread of these henipaviruses. More than 600 human infections have been reported in the literature, but information about biological processes related to transmission is limited; information on viral shedding was only available for 40 case-patients. There is substantial evidence demonstrating person-to-person transmission of NiV<sub>B</sub>, though there is also evidence that NiV<sub>M</sub> has been transmitted from person to person. Less direct evidence is available about the risk for person-to-person transmission of HeV, but animals infected with HeV shed more virus in the respiratory tract than those infected with NiV<sub>M</sub> suggesting potential for transmission. As the family of known henipaviruses continues to grow, shared protocols for conducting and reporting from human investigations and animal experiments are urgently needed to advance our understanding of transmission risk.

## Introduction

Zoonotic pathogens with demonstrated ability to infect and transmit between people are potential pandemic threats. In 2015, the World Health Organization named Nipah virus as one of the most dangerous emerging zoonotic disease threats because of its high case fatality and ability to transmit from person-to-person<sup>1</sup>. Nipah virus belongs to the genus *Henipavirus*, in the family *Paramyxoviridae*, along with Hendra virus, which has caused spillovers into horses in Australia and has also caused human infections with severe clinical outcomes<sup>2,3</sup>. Other henipaviruses, including Cedar virus, Mojiang virus, and Langya virus, have also been identified, but are much less common. The natural reservoirs for henipaviruses are pteropid bats, which are large fruit bats whose habitats span from South and Southeast Asia to East Africa and Australia.

Nipah virus outbreaks in Bangladesh and India have been reported since 2001 and have regularly been associated with person-to-person transmission<sup>1,2</sup>. Evidence suggests that transmission occurs through close contact with patients and their respiratory secretions<sup>1</sup>. However, person-to-person transmission was noted in the first outbreak identified in Malaysia and Singapore in 1998 and 1999<sup>2,4</sup>, where spillover into pigs and transmission to abattoir workers were salient features. While very similar, the Nipah virus strain identified in Bangladesh and India differed phylogenetically from the virus strain identified in the Malaysia and Singapore outbreak<sup>5</sup>. Hendra virus has not been associated with person-to-person transmission, and is distinct from Nipah virus; partial N gene fragments can be used to genotype viruses at the major clade level (i.e. Hendra vs. Nipah Malaysia vs. Nipah India/Bangladesh), but cannot mimic full-genome genetic variation<sup>5</sup>. Epidemiologic evidence about person-to-person transmission across countries has led to the suggestion that differences in transmissibility might be driven by genetic differences in henipavirus strains<sup>6</sup> and that the India/Bangladesh Nipah strain is better adapted to human spread than other henipaviruses. However, an outbreak of henipavirus in the Philippines in 2015 was associated with person-to-person transmission and the virus implicated in the outbreak was more closely related to the Malaysian Nipah strain than the South Asian strain<sup>7</sup>.

Understanding which henipaviruses have the greatest potential for person-to-person spread would improve our scientific understanding of their pandemic risk. If the India/Bangladesh Nipah strain poses the greatest risk for pandemic spread among known henipavirus strains, then resources should be targeted specifically to that geographic region to reduce pandemic risk. If the differences among known strains are merely an artifact of our epidemiologic observations rather than true variation in risk, then prevention strategies must address this broader henipavirus risk. We conducted a systematic review and meta analysis of human epidemiologic and clinical studies and studies of infections in mammals to compare transmission potential among the three henipaviruses known to infect humans: the India/Bangladesh strain of Nipah (NiV<sub>B</sub>), the Malaysian strain of Nipah (NiV<sub>M</sub>), and Hendra virus (HeV).

## Methods

### Literature search and study selection

We conducted a broad search of the literature using PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, and Scopus. Gray literature was searched using IndMED, KoreaMED, and WHO Global Index Medicus. Search strategies (Supplementary Table 1) were used to identify publications indexed by May 30, 2019 using the genus (“Henipavirus”) and species names (“Hendra” and “Nipah”). We reviewed the references of selected papers and identified 2 studies published prior to the use of ‘Hendra’, when it was referred to as ‘Equine morbillivirus’, that we included in the review, and 1 study on non-human primates which was published on May 29, 2019 but was not yet indexed.

Titles and abstracts were independently reviewed by two members of the study team and excluded if they lacked primary data, were an *in vitro* experiment, or were in languages other than English, French, Spanish, and Dutch. We also excluded studies of infection in bats as these do not provide evidence of potential human-to-human spread. Studies were included for data extraction if two team members reviewed the full text and confirmed that the study included human studies with primary data on secondary attack rates or transmission between people, or viral shedding (from any biological specimen) or viremia in either humans or experimentally infected mammals. Any discrepancies between reviewers were resolved through discussion between all reviewers.

#### Data extraction and analysis

For human studies, we extracted case-patient (or confirmed case) data including demographics, incubation period, symptomatology, whether or not the case was infected through person-to-person transmission, and clinical outcome. When available, we also extracted data on viral shedding by day post-illness onset.

We calculated the proportion of case-patients that experienced respiratory symptoms, median incubation period, case-fatality, and secondary attack rates and compared these metrics between henipaviruses. We defined respiratory symptoms as those case-patients that either were explicitly described to have respiratory distress, difficulty breathing, or “influenza-like illness (ILI) and encephalitis”, as some articles described case-patients with acute encephalitic syndrome as experiencing respiratory distress. We described the number of secondary cases for all Nipah virus cases where this information was published. We graphed the proportion of patients who shed virus in respiratory secretions by days since symptom onset using available data.

Information about viral shedding in humans was very rare so we relied primarily on animal studies to characterize and compare viral shedding. For experimental animal studies, we extracted data on animal species, route and dose of inoculation, and viral shedding by type of biological specimen collected and day post-inoculation. For observational studies of naturally infected animals, we extracted any information about viral shedding and type of biological specimen tested.

We identified the studies that used the same animal model, dose, and comparable route of inoculation but with different henipavirus strains to allow us to make comparisons of key characteristics of transmission potential, including quantity and duration of viral shedding. As exposure to respiratory secretions is considered the primary route of person-to-person transmission<sup>1</sup>, we focused our analysis on animal viral shedding from the respiratory tract. We examined the virus quantity (in genome equivalents) shed post inoculation in oral and nasal samples as a proxy measure of infectiousness for person-to-person transmission<sup>8,9</sup>, and we examined the infectious period, as determined by polymerase chain reaction (PCR) or real-time polymerase chain reaction (RT-PCR) viral detection in the days post inoculation, as a proxy measure of the duration of viral shedding. We also examined the duration of viral shedding prior to the onset of respiratory signs and the peak viral quantity both before and during respiratory signs.

## Results

We identified 2,465 studies that met our inclusion criteria for review (Supplementary Figure 1). After review, 52 human and 78 animal studies met the inclusion criteria for data extraction. The number of published studies increased over time, primarily among animal studies (Supplementary Figure 2).

### Human studies

We identified 52 studies with data on confirmed human henipavirus infections; 6 on Hendra virus in Australia and the remaining 46 on Nipah virus: 14 from Malaysia, 3 from Singapore, 1 from the Philippines (identified as Nipah-like virus), 19 from Bangladesh, and 9 from India (Supplementary Table 2). Twenty-nine studies (56%) investigated person-to-person transmission and 19 (37%) investigated viral shedding in oral, urine, or semen samples. Eleven studies (21%) investigated both transmission and viral shedding, and all such studies were from Bangladesh, India, and the Philippines.

### *Transmission potential of HeV*

Only 6 human cases of HeV infection have been reported in the published literature<sup>10–12</sup>, though 7 total human cases of HeV infection have occurred since 1994<sup>13</sup>, and none of these studies explicitly investigated person-to-person transmission. The presumptive exposure route was through contact with a sick or dead horse infected with HeV. However, one case of HeV had exposure to both an infected horse and a confirmed human case approximately 4 days prior to illness onset such that person-to-person transmission could not be ruled out<sup>14</sup>. The case in question developed symptoms 11 days after exposure to an infected horse (performed a nasal cavity lavage during the last 3 days of the horse's incubation period) and was exposed in the work-place to the index case during his incubation period and first two days of illness. The index case developed symptoms 9 days after exposure to the same infected horse during the same procedure and presented with symptoms to the clinic 4 days prior to the case in question<sup>14</sup>. Among the 6 cases, 50% had respiratory symptoms and 50% died (Table 2); the seventh HeV case also died<sup>13</sup>. Three HeV cases from the 2004 and 2008 HeV outbreaks had oral or nasal

and urine specimens collected to look for viral shedding (a total of 10 samples among the 3 case-patients were tested). Two of the 3 cases had evidence of HeV RNA by PCR within 15 days post illness onset (1 patient from oral/nasal specimen and 1 patient from urine specimen) both of whom also had signs of respiratory distress; the third case only had 1 sample taken 365 days post illness onset, which was negative. One case-patient had urine samples at days 23 and 30 post illness onset that had evidence of HeV RNA by PCR. There was no investigation of asymptomatic infections among exposed humans, though there was an investigation and evidence of asymptomatic infection among exposed horses<sup>11,15</sup>.

#### *Transmission potential of NiV<sub>M</sub>*

Studies on the transmission potential of NiV<sub>M</sub> were conducted in Malaysia, Singapore, and the Philippines, representing a total of 294 symptomatic human cases and 308 total infections (Table 2). Of the 18 studies on NiV<sub>M</sub> in humans, 4 investigated person-to-person transmission. In Malaysia and Singapore, although no healthcare workers who cared for hospitalized outbreak-related patients or abattoir workers (as the outbreak occurred near pig farms) developed symptoms suggestive of NiV<sub>M</sub> infection, they were investigated to identify evidence of IgG antibodies against NiV<sub>M</sub><sup>4,16</sup>. Three nurses in Malaysia and 22 healthcare workers in Singapore<sup>16</sup> had IgG antibody responses, though none of them had neutralizing antibodies. Ten abattoir workers (0.7%; 10/1469) were identified as having asymptomatic infections, however, the exposure was assumed to be infected pigs rather than infected humans<sup>16</sup>. Investigators of these outbreaks did not investigate person-to-person transmission to family caregivers, and the paper from Singapore specifically stated that transmission within households was not investigated because of concerns of inciting panic<sup>16</sup>. Further, as the outbreak was primarily investigated retrospectively, investigations of person-to-person transmission within households or family contacts of patients would have been very logistically difficult to do. The only evidence reported of transmission in households during the outbreak in Malaysia came from a report of an episode of late-onset encephalitis in a woman who did not live in the outbreak area, but who had traveled to the area during the outbreak to care for her aunt who was a Nipah case-patient. The woman was diagnosed with late-onset Nipah encephalitis 11 years after the initial outbreak<sup>17</sup>.

In the outbreak in the Philippines, 17 cases were identified. Seven cases slaughtered horses or consumed horse meat and 5 cases (29%) were exposed to other human cases but not to any horses. At least 12% ( $\geq 2/17$ ) of case-patients infected one other person; based on history of patient contacts, 5 secondary cases were caused by person-to-person transmission from a minimum of 2 cases (Table 1; Figure 1).

No patients infected with NiV<sub>M</sub> had any samples collected to investigate viral shedding. While 23% (32/138) of patients identified in the outbreaks in Malaysia and Singapore had respiratory symptoms, 94% (16/17) of the patients in the Philippines outbreak did (Table 2).

#### *Transmission potential of NiV<sub>B</sub>*

All 28 studies of NiV<sub>B</sub> outbreaks in Bangladesh and India, representing 342 total case-patients and 345 total infections (3 asymptomatic infections were found during a serological survey among patient contacts after the 2018 outbreak in India), have investigated the possibility of person-to-person transmission and secondary cases have been regularly identified. Twenty-nine case patients infected at least 1 other person (transmitter); 7% (7/94) of case-patients from India and 9% (22/248) of case patients from Bangladesh (Table 1). Among the 29 NiV<sub>B</sub> transmitters in the published literature, all were adults and 77% (20/26 where data was available) were males. Ninety-two percent of transmitters (24/26 with available data) had respiratory symptoms and all died.

Among case-patients who transmitted NiV<sub>B</sub>, 34% (10/29) transmitted to just 1 person and 24% (7/29) infected  $\geq 5$  other people; the size of outbreaks was heavily influenced by a few individuals who transmitted the virus to others as 8% of case-patients were responsible for the majority of transmission events (Figure 1). Roughly half (51%) of all 149 secondary cases were family members or non-professional caregivers and 9% were healthcare workers. In the 2018 India outbreak, during which detailed data was recorded, 22 of 23 total cases were a result of nosocomial transmission in 3 different hospitals.<sup>18</sup> The longest transmission chain reported was from a 2004 outbreak in Bangladesh, where 5 generations of transmission occurred<sup>19</sup>.

Seventeen patients from Bangladesh and 20 from India were investigated to identify viral shedding; 37 unique case-patients from the 2008 and 2013-2014 Bangladesh and 2001, 2007, and 2018 India Nipah virus outbreaks provided 55 unique samples including urine, oral/nasal, and semen samples. One study from the 2018 Nipah virus outbreak in India provided PCR cycle threshold (Ct) values to quantify viral load<sup>20</sup>, and one other study from Bangladesh<sup>1</sup> provided Ct values from throat swabs from case-patients, though no epidemiologic data accompanied these viral load data. There are 27 patients who contributed at least 1 oral or nasal swab sample in the published literature (total 37 samples), and 25 patients (total 32 samples) contributed sampled during their first week of illness. Seventy-six percent (28/37) of respiratory samples that were tested had evidence of viral RNA, and 81% (26/32) had evidence of viral RNA in the first week of illness. Respiratory samples were collected an average of 7.6 days post illness onset and samples that were positive were collected an average of 5.2 days after illness onset. More respiratory samples were collected 7 days post onset than other days (n=8) and all but 1 had evidence of NiV RNA by PCR (Figure 2). Only 1 patient was tested for viral RNA in semen and was found to be positive on days 16 and 26 but negative on days 42 and 59.

In Bangladesh, 1 study summarizing case findings from 14 years of data found contacts of Nipah patients were significantly more likely to be infected if they had a longer duration of exposure to the patient (>12 hours), or if they had contact with the patient's body fluids, particularly respiratory secretions<sup>1</sup>. Contacts also reported close contact with Nipah case-patients towards the end of life in Bangladesh<sup>21</sup>. Anecdotal evidence from the Kerala, India outbreak in 2018 suggests a similar pattern where contact nearer to the day of death resulted in transmission more often than contact earlier in the course of illness<sup>18</sup>.

For Nipah case-patients that died in Bangladesh and India and that we have information on time of symptom onset and death (N=37), the median number of days from symptom onset to death

was 6 days (IQR 5-7.5) for those that transmitted the virus to another person (mean 6.7 (3.5-13) days; N=24) compared to 7 (IQR 6 - 9.5) days for case-patients that died but did not transmit (mean 8.9 (3-31) days; N=39).

### Animal studies

We identified 78 animal studies with primary data on the amount or duration of viral shedding, encompassing 11 animal model types: non-human primate, ferret, hamster, horse, pig, mouse, cat, dog, guinea pig, rat, and shrew (Supplementary Table 3). Thirty-six studies investigated infections with NiV<sub>M</sub>, 21 with HeV, 6 with NiV<sub>B</sub>, 1 with Cedar virus<sup>22</sup> and 1 with Mojiang virus<sup>23</sup>. Six studies directly compared animals infected with NiV<sub>M</sub> and NiV<sub>B</sub>, five compared NiV<sub>M</sub> and HeV, and one compared NiV<sub>M</sub>, NiV<sub>B</sub> and HeV. The Nipah virus strains used in animal studies were derived from a case-patient from the 2004 Rajbari, Bangladesh outbreak<sup>19</sup> (NiV<sub>B</sub>) and a case patient from 1999 Malaysia outbreak among pig farmers<sup>24</sup> (NiV<sub>M</sub>). The Hendra virus strains used in animal studies were derived from infected horses from the 1994<sup>15</sup> and 2008<sup>25</sup> outbreaks in Brisbane, Australia.

The route and dose of inoculation and types of biological samples collected varied substantially between study protocols, even within the same animal model, which made inferences about differences between viruses difficult (Supplementary Table 3). Given the heterogeneity in study protocols and considering the primary route of person-to-person transmission is exposure to respiratory secretions<sup>1</sup>, we analyzed data from studies with PCR or RT-PCR results from oral, nasal, and/or nasopharyngeal samples that directly compared 2 or more henipavirus strains within the same experiment or that only inoculated animals with 1 strain but used nearly identical methods with at least 1 other study (Supplementary Figure 3). Ultimately, we limited our analysis to 8 studies where the same methods were used for more than 1 virus within the same animal model to allow for equivalent comparisons: 4 African green monkey and 4 ferret studies.

### *African green monkey studies*

The 4 African green monkey studies<sup>26-29</sup> included in the analysis were conducted by the same research group and used nearly identical protocols, though the route of inoculation differed slightly across studies (Mire et al 2014<sup>26</sup> and Geisbert et al<sup>27</sup> inoculated intratracheally, Mire et al 2016<sup>28</sup> and Mire et al 2019<sup>29</sup> inoculated intranasally and intratracheally). In all, 20 animals were inoculated with 10<sup>5</sup> plaque-forming units (PFU) with 3 different henipavirus strains: 7 with NiV<sub>B</sub>, 9 with NiV<sub>M</sub>, and 4 with HeV.

All animals inoculated with HeV and more than half of the animals inoculated with NiV<sub>M</sub> were first investigated for viral shedding 3 days post inoculation (Figure 4). One of 4 animals (25%) inoculated with HeV began shedding on day 3 post-inoculation and 50% were shedding by day 5; 67% (6/9) of animals inoculated with NiV<sub>M</sub> and 57% (4/7) of animals inoculated with NiV<sub>B</sub> were shedding by day 5. Shedding often occurred prior to the onset of respiratory symptoms for animals with detectable virus (59%, 10/17) (Figure 4, Table 3). Viral shedding typically continued until the animal reached criteria for euthanasia (Figure 4, Table 3). Time to



euthanasia was longer for African green monkeys inoculated with NiV<sub>M</sub> (mean 9.3 days, range 8-10 days) compared to NiV<sub>B</sub> (7.3 days, 7-8 days) and HeV (8.0 days, 8-8 days), contributing to longer shedding durations in animals inoculated with NiV<sub>M</sub> (4.8 days, 0-8 days) compared to NiV<sub>B</sub> (2.8 days, 0-5 days) and HeV (3.0 days, 0-6 days).

African green monkeys inoculated with NiV<sub>M</sub> developed respiratory signs later (mean 7.6 days, range 7-9) than those inoculated with NiV<sub>B</sub> (6.2, 5-7) and HeV (6.0, 5-7) (Figure 4, Table 3). This resulted in longer periods of viral shedding prior to the onset of respiratory signs or euthanasia in the case of animals without signs. Animals inoculated with NiV<sub>M</sub> shed virus for an average of 3.1 days (range 1-5) prior to signs, compared to 1.3 days (0-3) with NiV<sub>B</sub> and 0.7 days (0-2) with HeV.

In oral samples, we observed a mean virus quantity over 100-fold higher starting on day 5 post inoculation in African green monkeys inoculated with NiV<sub>B</sub> compared to NiV<sub>M</sub> and HeV (Figure 5A). The same pattern was not observed in nasal samples, where we noted a similar rise in virus quantity for both NiV<sub>B</sub> and NiV<sub>M</sub> by day 1 post inoculation (Supplementary Figure 4). Among animals with HeV, we observed consistently lower virus quantities in nasal samples with 2 of 4 animals having no detectable virus up to 7 days post inoculation; however, all 4 animals inoculated with HeV were inoculated intratracheally, as opposed to both intratracheal and intranasal routes in other studies. For each virus strain, the mean virus quantity increased in oral samples after onset of respiratory symptoms (Figure 5B, 5D). Animals inoculated with NiV<sub>B</sub> expressed the highest virus quantity in oral samples both before and during respiratory signs. There were no studies that reported on detection of culturable virus from oral or nasal specimens.

### *Ferret studies*

Four ferret studies, including 21 animals<sup>30-33</sup>, were included in the analysis. We were unable to compare virus quantities across studies given a lack of comparable individual-level measurements of virus quantity in the published literature. However, 2 studies directly compared virus quantities at the group-level. Leon and colleagues<sup>31</sup> inoculated groups of 4 ferrets intranasally with 5,000 50% tissue culture infectious dose (TCID<sub>50</sub>, approximately 3,500 PFU) of NiV<sub>B</sub>, NiV<sub>M</sub>, and HeV. On day 5 post inoculation, animals inoculated with NiV<sub>B</sub> had the lowest mean virus quantity in nasal samples and animals inoculated with HeV had the highest mean virus quantity in oral samples. Animals inoculated with NiV<sub>M</sub> had the lowest virus quantity in oral samples on days 6 and 7 post inoculation<sup>31</sup>. Clayton et al<sup>30</sup> oronasally inoculated 8 ferrets with NiV<sub>B</sub> and 7 ferrets with NiV<sub>M</sub>, all with 5,000 TCID<sub>50</sub>. They found no statistically significant difference in virus quantity over time in nasal samples (1 to 8 days post inoculation) but observed approximately 10-fold higher virus quantity in oral samples on days 5-6 and days 7-8 post inoculation among ferrets inoculated with NiV<sub>B</sub>. All but one animal in this study had culturable virus in their oral samples on the day of euthanasia.

Although we were unable to make individual-level comparisons of virus quantity, 3 of the ferret studies provided individual-level data on viral shedding duration across virus strains<sup>30,32,33</sup>. In all, 21 animals were inoculated with 5,000 TCID<sub>50</sub> with 3 different henipavirus strains: 8 with NiV<sub>B</sub>,

11 with NiV<sub>M</sub>, and 2 with HeV. Inconsistent timing and frequency of sampling over the course of infection led to difficulties in comparing time to viral shedding onset and duration of viral shedding between virus strains (Figure 6). However, once an animal began oral shedding, all additional samples had evidence of shedding until the day of euthanasia for all animals studied. The time point for euthanasia was based on severity of clinical signs. There were no notable differences in time from inoculation to euthanasia across strains: NiV<sub>B</sub> (mean, range: 7.6, 7-9), NiV<sub>M</sub> (8, 5-10), and HeV (7, 7-7). Daily individual-level clinical signs were not reported in any of four studies. Two animals infected with HeV had oral samples investigated for culturable virus on the day of euthanasia; 1 animal had culturable virus in their sample.<sup>32</sup>

## Discussion

We know very little about the diversity of zoonotic henipaviruses in nature. A new henipavirus infecting shrews and humans, but with no evidence of person-to-person transmission, was reported from China in 2022<sup>34</sup>. In 2021, a new Hendra virus was identified from fruit bats in Australia that had been previously missed by surveillance because the genetic differences in the virus made it undetectable by the PCR diagnostics routinely used<sup>35</sup>. Given the threat these viruses pose for human health, we should aim to understand as best we can the ecology of these viruses and the biological and social determinants of transmission and transmission potential. Our systematic review provides a summary of the evidence thus far, both about what we know and do not know about person-to-person transmission of henipaviruses, as well as the major gaps in how we investigate this phenomenon.

There is substantially more evidence demonstrating the transmission potential of NiV<sub>B</sub>, compared to NiV<sub>M</sub> or HeV, from both the studies of human epidemiology and animal infection. Our findings suggest that transmission likely occurs through viral shedding from the respiratory tract, with additional evidence of shedding in urine and semen. Two studies have demonstrated environmental contamination with viral RNA<sup>19,36</sup>, but the role of environmental contamination in transmission remains unknown. However, the role of viral shedding in urine or semen in contributing to onward transmission remains unexplored. The epidemiologic evidence suggests that the heterogeneity of pathogenesis, including the amount of virus being shed and clinical respiratory disease, determines the frequency of super-spreading events. Case-patients infected with NiV<sub>B</sub> in both India and Bangladesh who transmitted infection experienced more severe symptoms, particularly respiratory distress, all died, and exhibited a shorter time to death from illness onset than case-patients who did not transmit to others. If transmission between people is driven by the amount of virus shed in respiratory secretions and only a few case-patients transmit the virus to the majority of secondary cases, then we would expect high variation in the amount of virus shed by individuals as a major driver of human transmission potential. The substantial variation in the amount of virus shed between African green monkeys infected with NiV<sub>B</sub> in respiratory secretions supports the conclusion that differences in the number of cases each person infects may be primarily driven by the amount of virus they shed, which could be influenced by biological features of the individual and/or the virus strain.

Our review also suggests that NiV<sub>M</sub> poses a risk for person-to-person spread. First, there is evidence that NiV<sub>M</sub> has been transmitted from person to person, both from anecdotal evidence

in the case of a family caregiver with relapsing encephalitis<sup>17</sup> and demonstrated transmission in the Philippines outbreak. Given that less than 1 in 10 patients infect someone else in settings where person-to-person transmission does occur, and that most secondary cases reported have been family caregivers, it is possible that transmission between people simply went unnoticed in Malaysia or Singapore where this type of transmission between the case-patients was not actively investigated. Although non-human primates infected with NiV<sub>M</sub> did not shed as much virus as those infected with NiV<sub>B</sub>, they were symptomatic and shed virus longer, which could also pose a transmission advantage. The Philippines outbreak was small but showed epidemiologic features of person-to-person transmission very similar to outbreaks in Bangladesh and India, including the proportion of cases who transmitted to others, and the relative frequency of adult males with respiratory symptoms as transmitters. The proportion of case-patients with respiratory symptoms was greater in the Philippines than in Malaysia, possibly suggesting phenotypic diversity among the NiV<sub>M</sub> strain.

The potential for HeV to be transmitted between people is less clear but should not be discounted. With only 6 human cases of HeV reported in the literature and 7 human cases ever reported, there are too few observations to determine if there are real differences in the transmission potential in humans compared to NiV<sub>B</sub> or NiV<sub>M</sub>. In addition, most African green monkeys infected with HeV shed virus at similar times, and with accompanying respiratory signs, compared to monkeys infected with NiV<sub>B</sub> or NiV<sub>M</sub>. Furthermore, animals infected with HeV shed significantly higher titers of virus in respiratory specimens than animals infected with NiV<sub>M</sub> in the same study. If shedding high amounts of virus in respiratory secretions is important for transmission between people, then HeV may be more transmissible than NiV<sub>M</sub>.

Twenty-seven years have passed since the first human infection with a henipavirus was reported<sup>15</sup>, and there are >600 human infections reported in the literature, yet only 40 have had data investigating viral shedding reported. Many studies did not investigate transmission to household contacts<sup>7,16</sup>, and 1 outbreak in Siliguri, India, where nosocomial transmission was a key driver of the outbreak, provides too few details to recreate transmission chains or identify superspreading events<sup>37</sup>. Given that nosocomial spread has fueled many infectious disease outbreaks, understanding the details of transmission within healthcare settings is critical to designing effective containment and infection control strategies. Moreover, if we want to improve our understanding of the transmission potential of henipaviruses and distinguish the characteristics of these highly fatal viruses that might contribute to differential transmission dynamics, we need a systematic approach to human epidemiologic and clinical investigations and animal models. Standardized protocols to investigate person-to-person spread and biological and behavioral risk factors for transmission, including the potential for sexual transmission, across henipaviruses and settings would leverage opportunities to learn about these emerging viruses. Though a recent summary of person-to-person studies in Bangladesh provides a good start to this work<sup>1</sup>, more details about each case-patient would be useful to increase our ability to understand transmission potential.

Outbreak investigations should report as much granularity as possible on the route of exposure, timeline of infection and symptoms (e.g. incubation period), paired with serial oral/respiratory and blood specimens with viral load (or Ct values as an indicator), evaluation of other potentially

infectious body fluids (e.g. tears, semen, vaginal fluids), case fatality ratio (CFR), timing of death, proportion of transmitters, geographic distribution, spillover frequency, and cluster size<sup>38</sup>. The potential for transmission can be quantified by then establishing such measures as the secondary attack rate, duration of viral shedding, quantity of virus shed, and clinical signs and symptoms that promote transmission of the virus to others. Therefore, publishing detailed line lists from outbreaks could help to build a global database of henipavirus transmission that could be leveraged to improve our collective understanding over time.

The primary reason that henipaviruses are a concern for public health is the possibility that a more highly transmissible strain could emerge. Experimental infections of animals can provide unique opportunities to compare henipaviruses in terms of pathology and viral shedding in a standardized way that can help contextualize the highly imperfect observational epidemiologic data about transmission to assess public health risk. For example, the shedding of virus by African green monkeys prior to onset of overt signs of disease may suggest that transmission by humans could occur prior to symptom onset, though these patterns may also be artifacts of the extremely high infectious doses administered in animal infection models. However, the published experimental studies we identified in our review were largely unsuitable for providing meaningful comparisons because of differences in inoculation routes and titers, and frequency of and methods for measuring viremia and viral shedding. Moreover, these studies, as with the human studies, relied primarily on measurements of viral load using PCR, which does not differentiate viable from non-viable virus. These studies, including assessments of virus viability, are costly and time consuming and we should maximize their ability to inform our understanding of transmission through greater harmonization of protocols across labs and animal models. Increasing the diversity of virus strains used in these studies would provide additional insights into the role of viral genetics in transmission potential.

Though our review highlights NiV<sub>B</sub> as a greater threat to humans compared to the other henipavirus strains, we cannot dismiss the risk that the other known and yet undiscovered viruses may pose. As the family of known henipaviruses continues to grow, shared protocols for human investigations and animal experiments are urgently needed to capitalize on more opportunities to advance our understanding of transmission risk.

**Author contributions:** ESG conceived of the study idea; ESG and KHL worked with an informationist to design the search strategy; KHL, STH, AS, and FKJ performed the analyses; all authors reviewed studies for inclusion in the analysis, extracted data from studies, and contributed to manuscript writing.

**Competing interests:** The authors have no competing interests to declare.

**Materials and communications:** Correspondence related to this paper should be addressed to Emily S. Gurley, [egurley1@jhu.edu](mailto:egurley1@jhu.edu).

## Tables & Figures

**Table 1.** Description of person-to-person henipavirus transmission and characteristics of case-patients who infected others by henipavirus strain and country in the subset of studies where person-to-person transmission was identified, 2001 - 2018. All estimates below are based on the studies where relevant information was provided.


Virus	$NiV_M$	$NiV_B$	
Country	Philippines <sup>7*</sup>	Bangladesh <sup>1</sup>	India <sup>18,37,39</sup>
<i>Proportion of case-patients who were transmitters (i.e., infected someone else) (n/N)</i>	≥12% (≥2/17)	9% (22/248)	7% (7/94)
<i>Proportion of transmitters who were male (n/N)</i>	100% (2/2)	77% (17/22)	75% (3/4)
<i>Proportion of transmitters who were adults (n/N)</i>	100% (2/2)	77% (17/22)	100% (7/7)
<i>Proportion of transmitters with respiratory symptoms (n/N)</i>	≥50% (≥1/2)	90% (20/22)	100% (4/4)
<i>Proportion of secondary cases who were family</i>	≥60% (3/5)	≥45% (15/33)	≥54% (38/71)

*members or non-  
professional  
caregivers*

---

\*Based on article description, we assumed at least 2 transmitters, and at least one transmitter had substantial respiratory secretions implying respiratory symptoms.

**Figure 1.** The distribution of secondary cases per Nipah case-patient (offspring distribution) and the proportion of those who transmitted who were superspreaders in countries where any person-to-person transmission of henipaviruses has been observed – Bangladesh, India, and the Philippines, 2001 - 2018.



**Table 2.** The natural history of infection for henipaviruses (Hendra virus: HeV, Nipah virus - Malaysia: NiV<sub>M</sub>, and Nipah virus - India/Bangladesh: NiV<sub>B</sub>) by country of outbreak origin using data from outbreaks identified during the 2001-2018 time period. References are cited to indicate from where data was used to derive estimates for each metric.

<b>Virus</b>	<i>HeV</i>	<i>NiV<sub>M</sub></i>			<i>NiV<sub>B</sub></i>	
<b>Country</b>	Australia	Singapore	Malaysia	Philippines <sup>†</sup>	Bangladesh	India
<i>Proportion of individuals exposed with evidence of asymptomatic infection % (n/N)</i>	Not investigated	0.7% (10/1469) <sup>16</sup>	3% (4/1412) <sup>40</sup>	Not investigated	0% (0/1863) <sup>1</sup>	1.1% (3/279) <sup>†18,41,42</sup>
<i>Total number of infections (asymptomatic + symptomatic cases identified)</i>	6	22	269	17	248	97
<i>Proportion of all infections that are symptomatic % (n/N)</i>	100% (6/6)	55% (12/22)	98.5% (265/269)	100% (17/17)	100% (248/248)	97% (94/97)
<i>Median incubation period (range)</i>	7.5 days (5-16)	-	-	8 days (4-20)	9 days (6-14) <sup>43</sup>	10 days (6-18)
<i>Proportion of case-patients with respiratory signs or symptoms*** % (n/N)</i>	50% (3/6) <sup>†</sup>	50% (6/12) <sup>16,44</sup>	21% (26/126) <sup>†45,46</sup>	94% (16/17)	63% (152/243) <sup>1</sup>	67% (63/94)
<i>Case fatality % (n/N)</i>	50% (3/6)	0.08% (1/12)	40% (105/265) <sup>46</sup>	53% (9/17)	78% (193/248)	93% (26/28) <sup>**</sup>

<sup>†</sup>Includes cases with meningitis (1 case), severe influenza-like illness (5 cases), and acute encephalitis syndrome requiring ventilation (11 cases) in the Philippines outbreak<sup>7</sup>. No patients with meningitis or ILI died. We assume case-patients with acute encephalitic syndrome experienced respiratory distress based on the article description.



<sup>†</sup>279 serum samples (155 HCWs and 124 household and community contacts) tested after the 2018 India NiV outbreak. Of the 279 samples, 2 were IgM and IgG NiV positive and 1 was only IgM positive against NiV. The estimated overall seroprevalence was 1.08% (95% CI 0.37–3.11) (Kumar 2019<sup>42</sup>).


\*\*\*Respiratory signs and symptoms include cough, respiratory distress, difficulty breathing, influenza-like illness, encephalitic syndrome when mechanical ventilation use is indicated.

<sup>†</sup>Two case-patients developed influenza-like illness and another had signs of severe respiratory distress.


<sup>†</sup>Although investigated, no substantial respiratory symptoms were reported from Goh 2000<sup>45</sup> (February - June 1999 outbreak), but 13 case-patients reported non-productive cough which we include here as respiratory signs. Thirteen case-patients (40% of a total of 94 case-patients) from Wong 2002<sup>46</sup> (September 1998 - April 1999 outbreak) reported cough/respiratory symptoms.

\*\*Case-fatality reported for those cases that have data on outcome. Siliguri 2001 outbreak had an overall CFR of 68% (45/66) rendering the CFR for all cases 76% (71/94).

**Figure 2.** Evidence for henipavirus viral shedding in (a) 8 human oral/nasal and urine samples by days post illness onset using polymerase chain reaction (PCR) testing for 3 unique case-patients with confirmed Hendra virus (HeV) infection from the 2004 and 2008 HeV outbreaks in Australia, and (b) 55 human oral/nasal, semen and urine samples by days post illness onset using PCR testing for 37 unique case-patients with confirmed Nipah virus (NiV<sub>B</sub>) infection from the 2008 and 2013-2014 Bangladesh and 2001, 2007, and 2018 India NiV outbreaks. Though not shown in this figure, two additional urine samples from case-patients with HeV were PCR tested at days 365 (1 case-patient from the 2004 HeV outbreak) and 548 (1 case-patient from the 2008 HeV outbreak) post illness onset. Both of these urine samples were PCR negative.



**Figure 4.** Comparing onset and duration of oral viral shedding and respiratory signs, and timing of humane endpoints among African green monkeys (N=20) infected with Hendra virus, Nipah virus Bangladesh (NiV<sub>B</sub>), or Nipah virus Malaysia (NiV<sub>M</sub>), by study. The studies used here, including the route of inoculation employed, are as follows: Mire 2014<sup>26</sup> (intratracheal; N=4), Geisbert 2014<sup>27</sup> (intratracheal; N=5), Mire 2016<sup>28</sup> (intratracheal & intranasal; N=10), Mire 2019<sup>29</sup> (intratracheal & intranasal; N=1).




**Table 3.** Comparing the trajectory of infection, including timing of viral shedding, respiratory signs, and euthanasia among African green monkeys infected with Hendra virus (HeV), Nipah virus Malaysia (NiV<sub>M</sub>), or Nipah virus Bangladesh (NiV<sub>B</sub>) in studies that used similar protocols. (N=20) The sample size (n/N) indicates how many animals provided data for the estimation of reported time in days.


Time in Days	HeV Mean number of days (range) n/N	NiV <sub>M</sub> Mean number of days (range) n/N	NiV <sub>B</sub> Mean number of days (range) n/N
Time from inoculation to:			
Respiratory signs, among animals with signs	6.0 (5-7) 4/4	7.6 (7-9) 8/9	6.2 (5-7) 6/7
Euthanasia, among animals euthanized	8.0 (8-8) 3/4	9.3 (8-10) 7/9	7.3 (7-8) 7/7
Oral shedding, among animals with shedding	5.0 (3-7) 3/4	3.6 (3-5) 7/9	5 (3-7) 7/7
Total oral shedding duration, among all animals <sup>†</sup>	3.0 (0-6) 4/4	4.4 (0-8) 9/9	3.0 (0-5) 7/7
Duration of oral shedding prior to respiratory signs or euthanasia, among animals with shedding	0.7 (0-2) 3/4	3.1 (1-5) 7/9	1.3 (0-3) 7/7

<sup>†</sup>Endpoint was defined as the last day with a positive PCR result. Day of euthanasia was used instead for 1 HeV animal (O7923) not tested on the day of euthanasia.

**Figure 5.** Comparing virus quantity in oral samples of African green monkeys infected with Hendra virus (HeV) or Nipah virus Bangladesh (NiV<sub>B</sub>) compared with Nipah virus Malaysia (NiV<sub>M</sub>) in studies with similar study protocols, by route of inoculation. (a) Virus quantity by days post inoculation and (b) peak quantity before and during respiratory signs in animals inoculated intratracheally with NiV<sub>M</sub> and NiV<sub>B</sub><sup>26,27</sup> (N=9). (c) Virus quantity by days post inoculation and (d) peak quantity before and during respiratory signs in animals inoculated intranasally/intratracheally<sup>28,29</sup> with NiV<sub>M</sub> and HeV (N=11). Quantities are shown as log genome equivalents. Error bars represent mean and standard error. Four African green monkeys were excluded from b and d as no samples were positive by PCR and/or the animals did not develop respiratory signs.



**Figure 6.** Comparing duration of oral viral shedding, respiratory signs, and timing of humane endpoints among ferrets (N=21) infected with Hendra virus, Nipah virus Bangladesh (NiV<sub>B</sub>), or Nipah virus Malaysia (NiV<sub>M</sub>), by study.



## References

1. Nikolay, B. *et al.* Transmission of Nipah Virus—14 Years of Investigations in Bangladesh. *N. Engl. J. Med.* **380**, 1804–1814 (2019).
2. Luby, S. P. & Gurley, E. S. Epidemiology of henipavirus disease in humans. *Curr. Top. Microbiol. Immunol.* **359**, 25–40 (2012).
3. Marsh, G. A. *et al.* Cedar virus: a novel Henipavirus isolated from Australian bats. *PLoS Pathog.* **8**, e1002836 (2012).
4. Mounts, A. W. *et al.* A cohort study of health care workers to assess nosocomial transmissibility of Nipah virus, Malaysia, 1999. *J. Infect. Dis.* **183**, 810–813 (2001).
5. Whitmer, S. L. M. *et al.* Inference of Nipah virus evolution, 1999-2015. *Virus Evol* **7**, veaa062 (2021).
6. Harcourt, B. H. *et al.* Genetic characterization of Nipah virus, Bangladesh, 2004. *Emerg. Infect. Dis.* **11**, 1594–1597 (2005).
7. Ching, P. K. G. *et al.* Outbreak of henipavirus infection, Philippines, 2014. *Emerg. Infect. Dis.* **21**, 328–331 (2015).
8. Lau, L. L. H. *et al.* Viral shedding and clinical illness in naturally acquired influenza virus infections. *J. Infect. Dis.* **201**, 1509–1516 (2010).
9. Quinn, T. C. *et al.* Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. *N. Engl. J. Med.* **342**, 921–929 (2000).
10. Hanna, J. N. *et al.* Hendra virus infection in a veterinarian. *Medical Journal of Australia* vol. 185 562–564 Preprint at <https://doi.org/10.5694/j.1326-5377.2006.tb00692.x> (2006).
11. Paterson, D. L., Murray, P. K. & McCormack, J. G. Zoonotic disease in Australia caused by a novel member of the paramyxoviridae. *Clin. Infect. Dis.* **27**, 112–118 (1998).
12. Wong, K. T. *et al.* Human Hendra virus infection causes acute and relapsing encephalitis. *Neuropathol. Appl. Neurobiol.* **35**, 296–305 (2009).
13. Summary of human cases of Hendra virus infection - Control guidelines.

<https://www.health.nsw.gov.au/Infectious/controlguideline/Pages/hendra-case-summary.aspx>.

14. Playford, E. G. *et al.* Human Hendra virus encephalitis associated with equine outbreak, Australia, 2008. *Emerg. Infect. Dis.* **16**, 219–223 (2010).
15. Selvey, L. A. *et al.* Infection of humans and horses by a newly described morbillivirus. *Med. J. Aust.* **162**, 642–645 (1995).
16. Chan, K. P. *et al.* A survey of Nipah virus infection among various risk groups in Singapore. *Epidemiol. Infect.* **128**, 93–98 (2002).
17. Abdullah, S., Chang, L.-Y., Rahmat, K., Goh, K. J. & Tan, C. T. Late-onset Nipah virus encephalitis 11 years after the initial outbreak: A case report. *Neurology Asia* **17**, (2012).
18. Arunkumar, G. *et al.* Outbreak Investigation of Nipah Virus Disease in Kerala, India, 2018. *J. Infect. Dis.* **219**, 1867–1878 (2019).
19. Gurley, E. S. *et al.* Person-to-person transmission of Nipah virus in a Bangladeshi community. *Emerg. Infect. Dis.* **13**, 1031–1037 (2007).
20. Yadav, P. D. *et al.* Nipah Virus Sequences from Humans and Bats during Nipah Outbreak, Kerala, India, 2018. *Emerg. Infect. Dis.* **25**, 1003–1006 (2019).
21. Lee, K. H. *et al.* Changing Contact Patterns Over Disease Progression: Nipah Virus as a Case Study. *J. Infect. Dis.* **222**, 438–442 (2020).
22. Schountz, T. *et al.* Differential Innate Immune Responses Elicited by Nipah Virus and Cedar Virus Correlate with Disparate In Vivo Pathogenesis in Hamsters. *Viruses* **11**, (2019).
23. Wu, Z. *et al.* Novel Henipa-like virus, Mojiang Paramyxovirus, in rats, China, 2012. *Emerg. Infect. Dis.* **20**, 1064–1066 (2014).
24. Chua, K. B. *et al.* Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. *Lancet* **354**, 1257–1259 (1999).
25. Field, H. *et al.* Hendra virus outbreak with novel clinical features, Australia. *Emerg. Infect.*




- Dis.* **16**, 338–340 (2010).
26. Mire, C. E. *et al.* A recombinant Hendra virus G glycoprotein subunit vaccine protects nonhuman primates against Hendra virus challenge. *J. Virol.* **88**, 4624–4631 (2014).
  27. Geisbert, T. W. *et al.* Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody. *Sci. Transl. Med.* **6**, 242ra82 (2014).
  28. Mire, C. E. *et al.* Pathogenic Differences between Nipah Virus Bangladesh and Malaysia Strains in Primates: Implications for Antibody Therapy. *Sci. Rep.* **6**, 30916 (2016).
  29. Mire, C. E. *et al.* Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease. *Emerg. Infect. Dis.* **25**, 1144–1152 (2019).
  30. Clayton, B. A. *et al.* Transmission routes for nipah virus from Malaysia and Bangladesh. *Emerg. Infect. Dis.* **18**, 1983–1993 (2012).
  31. Leon, A. J. *et al.* Host gene expression profiles in ferrets infected with genetically distinct henipavirus strains. *PLoS Negl. Trop. Dis.* **12**, e0006343 (2018).
  32. Pallister, J. *et al.* A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge. *Vaccine* **29**, 5623–5630 (2011).
  33. Bossart, K. N. *et al.* A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. *PLoS Pathog.* **5**, e1000642 (2009).
  34. Zhang, X.-A. *et al.* A Zoonotic Henipavirus in Febrile Patients in China. *N. Engl. J. Med.* **387**, 470–472 (2022).
  35. Wang, J. *et al.* A new Hendra virus genotype found in Australian flying foxes. *Virol. J.* **18**, 197 (2021).
  36. Hassan, M. Z. *et al.* Contamination of hospital surfaces with respiratory pathogens in Bangladesh. *PLoS One* **14**, e0224065 (2019).
  37. Harit, A. K. *et al.* Nipah/Hendra virus outbreak in Siliguri, West Bengal, India in 2001. *Indian*

- J. Med. Res.* **123**, 553–560 (2006).
38. Nikolay, B. *et al.* A Framework to Monitor Changes in Transmission and Epidemiology of Emerging Pathogens: Lessons From Nipah Virus. *J. Infect. Dis.* **221**, S363–S369 (2020).
  39. Arankalle, V. A. *et al.* Genomic characterization of Nipah virus, West Bengal, India. *Emerg. Infect. Dis.* **17**, 907–909 (2011).
  40. Ali, R. *et al.* Nipah Virus Infection Among Military Personnel Involved in Pig Culling during an Outbreak of Encephalitis in Malaysia, 1998-1999. *Emerging Infectious Disease journal* **7**, 759 (2001).
  41. Arunkumar, G. *et al.* Persistence of Nipah Virus RNA in Semen of Survivor. *Clin. Infect. Dis.* **69**, 377–378 (2019).
  42. Kumar, C. P. G. *et al.* Infections among contacts of patients with Nipah virus, India. *Emerg. Infect. Dis.* **25**, 1007–1010 (2019).
  43. Luby, S. P., Gurley, E. S. & Jahangir Hossain, M. Transmission of Human Infection with Nipah Virus. *Clinical Infectious Diseases* vol. 49 1743–1748 Preprint at <https://doi.org/10.1086/647951> (2009).
  44. Chew, M. H. *et al.* Risk factors for Nipah virus infection among abattoir workers in Singapore. *J. Infect. Dis.* **181**, 1760–1763 (2000).
  45. Goh, K. J. *et al.* Clinical features of Nipah virus encephalitis among pig farmers in Malaysia. *N. Engl. J. Med.* **342**, 1229–1235 (2000).
  46. Wong, K. T. *et al.* Nipah virus infection: pathology and pathogenesis of an emerging paramyxoviral zoonosis. *Am. J. Pathol.* **161**, 2153–2167 (2002).


## Supplementary Figure 1. Study selection




**Supplementary Figure 2.** Studies included in systematic review, by study type and year of publication.



### Supplementary Figure 3. Reasons for animal study exclusion.



**Supplementary Figure 4.** Virus quantity in nasal samples of African green monkeys inoculated in studies with similar study protocols. Quantities are shown as log genome equivalents by day post inoculation (A) and as the peak value before and during respiratory signs (B). Error bars represent mean and standard error. Four African green monkeys were excluded from B as no samples were positive by PCR and/or did not develop respiratory signs.



**Supplementary Table 1. Electronic databases and search strategies**

Electronic database	Search strategy
PubMed	("Henipavirus"[Mesh] OR "Henipavirus Infections"[Mesh]) OR (Henipa*[tw] OR hendra*[tw] OR nipah*[tw])
Embase	('henipavirus'/exp OR 'henipavirus infection'/exp) OR ((Henipa* OR hendra* OR nipah*):ti,ab,kw)
Cochrane Central Register of Controlled Trials	MeSH descriptor: [Henipavirus] explode all trees OR MeSH descriptor: [Henipavirus Infections] explode all trees OR (Henipa* OR hendra* OR nipah*)
Web of Science	TS=(Henipa* OR hendra* OR nipah*)
Scopus	TITLE-ABS-KEY: henipa* OR hendra* OR nipah*
IndMED	Henipa OR Henipavirus OR hendra OR hendra virus OR nipah OR nipah virus
KoreaMED	Henipa* OR hendra* OR nipah*
WHO Global Index Medicus	Henipa* OR Hendra* OR Nipah* OR MH:B04.820.455.600.650.400 OR MH:C02.782.580.600.400 OR MH:B04.820.455.600.650.400.400 OR MH:B04.820.455.600.650.400.550

**Supplementary Table 2.** Studies published through May 2019 on human henipavirus infections, by year and country (N=52)

Virus	Country	Year	Study	Investigated person-to-person transmission	Investigated viral shedding
Hendra	Australia	1995	Selvey LA, et al. Infection of humans and horses by a newly described morbillivirus	+	-
Hendra	Australia	1998	Paterson DL, et al. Zoonotic Disease in Australia Caused by a Novel Member of the Paramyxoviridae	+	-
Hendra	Australia	2006	Hanna JN, et al. Hendra virus infection in a veterinarian	-	-
Hendra	Australia	2009	Wong KT, et al. Human Hendra virus infection causes acute and relapsing encephalitis	-	-
Hendra	Australia	2010	Playford EG, et al. Human Hendra virus encephalitis associated with equine outbreak, Australia, 2008	-	+
Hendra	Australia	2012	Taylor C, et al. No evidence of prolonged Hendra virus shedding by 2 patients, Australia	-	+
Nipah	Malaysia	1999	Chua KB, et al. Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia	-	-
Nipah	Malaysia	2000	Premalatha GD, et al. Assessment of Nipah Virus Transmission Among Pork Sellers in Seremban Malaysia	-	-
Nipah	Malaysia	2000	Parashar UD, et al. Case-Control Study of Risk Factors for Human Infection with a New Zoonotic Paramyxovirus, Nipah Virus, during a 1998–1999 Outbreak of Severe Encephalitis in Malaysia	-	-
Nipah	Malaysia	2000	Goh KJ, et al. Clinical features of Nipah virus encephalitis among pig farmers in Malaysia	-	+



Nipah	Malaysia	2000	Amal NM, et al. Risk factors for Nipah virus transmission, Port Dickson, Negeri Sembilan, Malaysia: results from a hospital-based case-control study	-	-
Nipah	Malaysia	2000	Chua KB, et al. High mortality in Nipah encephalitis is associated with presence of virus in cerebrospinal fluid	-	-
Nipah	Malaysia	2001	Wong SC, et al. Late presentation of Nipah virus encephalitis and kinetics of the humoral immune response	-	-
Nipah	Malaysia	2001	Chua KB, et al. The presence of Nipah virus in respiratory secretions and urine of patients during an outbreak of Nipah virus encephalitis in Malaysia	-	+
Nipah	Malaysia	2001	Sahani M, et al. Nipah virus infection among abattoir workers in Malaysia, 1998-1999	-	-
Nipah	Malaysia	2001	Mounds AW, et al. A cohort study of health care workers to assess nosocomial transmissibility of Nipah virus, Malaysia, 1999	+	-
Nipah	Malaysia	2001	Ali R, et al. Nipah virus among military personnel involved in pig culling during an outbreak of encephalitis in Malaysia, 1998-1999	-	-
Nipah	Malaysia	2002	Tan CT, et al. Relapsed and late-onset Nipah encephalitis	-	-
Nipah	Malaysia	2002	Wong KT, et al. Nipah virus infection: pathology and pathogenesis of an emerging paramyxoviral zoonosis	-	-
Nipah	Malaysia	2012	Abdullah S, et al. Late-onset Nipah virus encephalitis 11 years after the initial outbreak: A case report	+	-

Nipah	Singapore	1999	Paton NI, et al. Outbreak of Nipah-virus infection among abattoir workers in Singapore	-	-
Nipah	Singapore	2000	Chew MHL, et al. Risk factors for Nipah virus infection among abattoir workers in Singapore	-	-
Nipah	Singapore	2002	Chan KP, et al. A survey of Nipah virus infection among various risk groups in Singapore	+	-
Nipah	Bangladesh	2004	Hsu V, et al. Nipah Virus Encephalitis Reemergence, Bangladesh	+	-
Nipah	Bangladesh	2004	WHO. Nipah virus outbreak(s) in Bangladesh, January-April 2004	+	-
Nipah	Bangladesh	2006	Luby SP, et al. Foodborne transmission of Nipah virus, Bangladesh	+	-
Nipah	Bangladesh	2007	Gurley ES, et al. Risk of nosocomial transmission of Nipah virus in a Bangladesh Hospital	+	-
Nipah	Bangladesh	2007	Gurley ES, et al. Person-to-person transmission of Nipah virus in a Bangladeshi community	+	+
Nipah	Bangladesh	2008	Hossain MJ, et al. Clinical presentation of Nipah virus infection in Bangladesh	-	-
Nipah	Bangladesh	2008	Montgomery JM, et al. Risk factors for Nipah virus encephalitis in Bangladesh	+	-
Nipah	Bangladesh	2010	Homaira N, et al. Cluster of Nipah Virus Infection, Kushtia District, Bangladesh, 2007	+	-
Nipah	Bangladesh	2010	Homaira N, et al. Nipah virus outbreak with person-to-person transmission in a district of Bangladesh, 2007	+	-

Nipah	Bangladesh	2012	Rahman MA, et al. Date palm sap linked to Nipah virus outbreak in Bangladesh, 2008	+	+
Nipah	Bangladesh	2012	Lo MK, et al. Characterization of Nipah virus from outbreaks in Bangladesh, 2008-2010	-	+
Nipah	Bangladesh	2013	Sazzad HMS et al. Nipah virus infection outbreak with nosocomial and corpse-to-human transmission, Bangladesh	+	+ (overlapping study with Lo 2012)
Nipah	Bangladesh	2015	Sazzad HMS, et al. Exposure-Based Screening for Nipah Virus Encephalitis, Bangladesh	+	-
Nipah	Bangladesh	2015	Naser AM, et al. Integrated cluster- and case-based surveillance for detecting stage III zoonotic pathogens: an example of Nipah virus surveillance in Bangladesh.	+	-
Nipah	Bangladesh	2016	Islam MS, et al. Nipah virus transmission from bats to humans associated with drinking traditional liquor made from date palm sap, Bangladesh, 2011-2014	+	-
Nipah	Bangladesh	2016	Hegde ST, et al. Investigating Rare Risk Factors for Nipah Virus in Bangladesh: 2001-2012.	+	-
Nipah	Bangladesh	2016	Chakraborty A, et al. Evolving epidemiology of Nipah virus infection in Bangladesh: Evidence from outbreaks during 2010-2011	+	-
Nipah	Bangladesh	2018	Hassan MZ, et al. Nipah virus contamination of hospital surfaces during outbreaks, Bangladesh, 2013-2014	+	+
Nipah	Bangladesh	2019	Nikolay B, et al. Transmission of Nipah virus – 14 years of investigations in Bangladesh	+	+
Nipah	India	2006	Chadha MS, et al Nipah virus-associated encephalitis outbreak, Siliguri, India	+	+

Nipah	India	2006	Harit AK, et al. Nipah/Hendra virus outbreak in Siliguri, West Bengal, India in 2001	+	+
Nipah	India	2011	Arankalle VA, et al. Genomic characterization of Nipah virus, West Bengal, India.	+	+
Nipah	India	2018	Thulaseedaran NKA, et al. Case series on the recent Nipah epidemic in Kerala	+	+
Nipah	India	2018	Arunkumar G, et al. Outbreak investigation of Nipah virus disease in Kerala, India, 2018	+	+
Nipah	India	2018	Arunkumar G, et al. Persistence of Nipah virus RNA in semen of survivor	-	+
Nipah	India	2019	Arunkumar G, et al. Adaptive immune responses in humans during Nipah virus acute and convalescent phases of infection	-	+
Nipah	India	2019	Yadav PD, et al. Nipah virus sequences from humans and bats during Nipah outbreak, Kerala, India, 2018	-	+ (from secondary cases)
Nipah	India	2019	Kumar CPG, et al. Infections among contacts of patients with Nipah virus, India	+	-
Nipah-like	Philippines	2015	Ching PKG, et al. Outbreak of henipavirus infection, Philippines, 2014	+	+

**Supplementary Table 3.** Studies published through May 2019 on animal henipavirus infections, by first author name, year of publication, and animal model (N=78)

First Author	Publication Year	Animal model	Virus investigated			
			HeV	NiV <sub>M</sub>	NiV <sub>B</sub>	Other Virus

Mire*	2019	African green monkey			x	
Lo	2019	African green monkey			x	
Hammoud	2018	African green monkey		x		
Cong	2017	African green monkey		x		
Mire*	2016	African green monkey		x	x	
Johnston	2015	African green monkey		x		
Prescott	2015	African green monkey		x		
Geisbert*	2014	African green monkey		x		
Mire*	2014	African green monkey	x			
Yoneda	2013	African green monkey		x		
Bossart	2012	African green monkey		x		
Bossart	2011	African green monkey	x			
Geisbert	2010	African green monkey		x		
Rockx	2010	African green monkey	x			
Alimonti	2014	Cynomolgus macaques	x	x		
Marianneu	2010	Squirrel monkey		x		
Leon*	2018	Ferret	x	x	x	

Clayton	2016	Ferret		x	x	
Satterfield	2016	Ferret		x		
Satterfield	2015	Ferret		x		
Marsh	2013	Ferret	x			
Mire	2013	Ferret		x		
Pallister	2013	Ferret			x	
Clayton*	2012	Ferret		x	x	
Pallister*	2011	Ferret	x			
Bossart*	2009	Ferret		x		
Pallister	2009	Ferret		x		
Schountz	2019	Syrian hamster				Cedar virus
Dawes	2018	Syrian hamster		x		
Walpita	2017	Syrian hamster		x		
Baseler	2016	Syrian hamster		x	x	
Borisevich	2016	Syrian hamster	x	x		
DeBuysscher	2016	Syrian hamster		x		
Guillaume-Vasselin	2016	Hamster	x			

DeBuysscher	2014	Syrian hamster		x		
de Wit	2014	Syrian hamster			x	
Lo	2014	Syrian hamster		x		
DeBuysscher	2013	Syrian hamster		x	x	
Ploquin	2013	Syrian hamster	x	x		
Munster	2012	Syrian hamster		x		
de Wit	2011	Syrian hamster		x		
Mathieu	2011	Syrian hamster		x		
Rockx	2011	Syrian hamster	x	x		
Guillaume	2009	Syrian hamster	x			
Georges-Courbot	2006	Syrian hamster		x		
Guillaume	2004	Syrian hamster		x		
Wong	2003	Syrian hamster		x		
Cowled	2017	Horse	x			
Ball	2014	Horse	x			
Middleton	2014	Horse	x			
Marsh	2011	Horse	x			

Field	2010	Horse	x			
Hooper	2000	Horse	x			
Williamson	1998	Horse, Cat	x			
Kasloff	2019	Landrace pig			x	
Pickering	2016	Landrace pig	x	x		
Li	2010	Guinea pig, Landrace pig, Gottingen minipig	x			
Berhane	2008	Landrace pig		x		
Weingartl	2006	Landrace pig		x		
Weingartl	2005	Landrace pig		x		
AbuBakar	2004	Pig		x		
Tanimura	2004	Pig		x		
Middleton	2002	Pig, Domestic shorthair cat		x		
Escaffre	2017	Mouse (NOD-SCID/ $\gamma$ c(null))			x	
Dups	2014	Mouse (BALB/c, C57BL/6)		x	x	
Valbuena	2014	Mouse (NOD-SCID/ $\gamma$ c(null))		x		
Dhondt	2013	Mouse (C57BL/6, IFNAR-KO)	x	x		
Dups	2012	Mouse (BALB/c, C57BL/6)	x			



Wu	2014	Buff-breasted rat, Musk shrew				Mojiang virus
McEachern	2008	Domestic shorthair cat		x		
Mungall	2007	Domestic shorthair cat fetus		x		
Mungall	2006	Domestic shorthair cat		x		
Middleton	2017	Beagle dog, Ferrets	x			
Halima	2015	Terrier dog	x			
Kirkland	2015	Fox terrier dog	x			
Torres-Velez	2008	Guinea pig		x		
Williamson	2001	Guinea pig	x			
Williamson	1999	Guinea pig	x			

\*included in comparison analysis

\*\* PFU converted to TCID<sub>50</sub> (PFU/0.7 = TCID<sub>50</sub>)

